Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A1 | P30531 | 2/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.43 |
| ▸ | SLC6A12 | P48065 | 2/20 | 0.43 |
| ▸ | SLC6A11 | P48066 | 2/20 | 0.43 |
| ▸ | SLC6A13 | Q9NSD5 | 2/20 | 0.43 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRR1 | P24046 | 1/20 | 0.43 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.43 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.37 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.37 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.37 |
| ▸ | ADH1B | P00325 | 4/20 | 0.36 |
| ▸ | ADH1A | P07327 | 4/20 | 0.36 |
| ▸ | ADH7 | P40394 | 4/20 | 0.36 |
| ▸ | ADH1C | P00326 | 3/20 | 0.36 |
| ▸ | ADH4 | P08319 | 2/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | NAMPT | P43490 | 1/20 | 0.33 |
| ▸ | ACP1 | P24666 | 6/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3956314 | 0.89 | GNAI3 (0.42) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL5651899 | 0.78 | — | — | |
| SCHEMBL7357879 | 0.78 | SLC6A1 (0.46) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL3715748 | 0.77 | — | — | |
| SCHEMBL4136214 | 0.77 | GNAI3 (0.41) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL12524730 | 0.76 | GNAO1 (0.45) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL11799788 | 0.76 | SLC6A1 (0.48) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 | |
| SCHEMBL6443208 | 0.75 | — | — | |
| SCHEMBL3024930 | 0.75 | ADH1B (0.54) | ADH1BADH1AADH7ADH1CADH4 | |
| SCHEMBL28485229 | 0.74 | SIGMAR1 (0.53) | SLC6A1GABRA5GABRB2SLC6A12SLC6A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS AG (CH) | 2019-05-09 | — | — | US | disclosed |
| US-9452994-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-09-27 | — | — | US | disclosed |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | FLUBACHER DIETMAR (DE) | 2016-09-01 | — | — | US | disclosed |
| EP-3040333-A1 | CRYSTALLINE FORMS OF 5-(2,6-DI-4-MORPHOLINYL-4-PYRIDMIDINYL)-4-TRIFLUOROMETHYLPYRIDIN-2-AMINE, A PIK3 INHIBITOR | Novartis AG (CH) | 2016-07-06 | — | — | EP | disclosed |
| US-9359326-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2016-06-07 | — | — | US | disclosed |
| US-9181215-B2 | Manufacturing process for pyrimidine derivatives | NOVARTIS AG (CH) | 2015-11-10 | — | — | US | disclosed |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2015-08-20 | — | — | US | disclosed |
| EP-2295402-B1 | Antibacterial agents | UNIV WASHINGTON (US) | 2015-08-12 | — | — | EP | disclosed |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | NOVARTIS PHARMACEUTICALS CORPORATION | 2015-05-21 | — | — | US | disclosed |
| EP-2637665-B1 | DEXAMETHASONE COMBINATION THERAPY | UNIV TEXAS (US) | 2015-04-08 | — | — | EP | disclosed |
| EP-1587473-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1575940-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1537099-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2005-06-08 | — | — | EP | disclosed |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2005-03-31 | — | — | US | disclosed |
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | UNIVERSITY OF WASHINGTON | 2004-11-18 | — | — | US | disclosed |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | NOVARTIS AG (CH) | 2004-09-09 | — | — | US | disclosed |
| WO-2004060308-A2 | THIOSEMICARBAZONES AS ANTI-VIRALS AND IMMUNOPOTENTIATORS | CHIRON CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004048365-A1 | 2,4,6-TRISUBSTITUTED PYRIMIDINES AS PHOSPHOTIDYLINOSITOL (PI) 3-KINASE INHIBITORS AND THEIR USE IN THE TREATMENT OF CANCER | CHIRON CORPORATION (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2004-04-22 | — | — | US | disclosed |
| WO-2004018455-A1 | PYRROLE BASED INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2004-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040229955-A1 | intracellular inhibition of bacterial polypeptide deformylase in gramnegative bacteria, | PDF, DDOST, MRPL21 | SLC6A1 2098/4885GABRA5 3834/4885GABRB2 3175/4885 |
| US-20150141426-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | SLC6A1 1330/4885GABRA5 3679/4885GABRB2 4537/4885 |
| US-20040176385-A1 | Small molecule PI 3-kinase inhibitors and methods of their use | PI4KB, PI4KA, PDPK1 | SLC6A1 3249/4885GABRA5 4108/4885GABRB2 3669/4885 |
| US-20050069555-A1 | Thiosemicarbazones as anti-virals and immunopotentiators | MAVS, IRF3, HAVCR2 | SLC6A1 1308/4885GABRA5 2133/4885GABRB2 630/4885 |
| US-20150232446-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | SLC6A1 430/4885GABRA5 608/4885GABRB2 2915/4885 |
| US-20040077707-A1 | Pyrrole based inhibitors of glycogen synthase kinase 3 | GSK3B, GSK3A, PYGB | SLC6A1 4029/4885GABRA5 3598/4885GABRB2 3156/4885 |
| US-20190134052-A1 | DOSAGE REGIMEN FOR A PI-3 KINASE INHIBITOR | PIK3CA, PIK3CD, PIK3R5 | SLC6A1 1330/4885GABRA5 3679/4885GABRB2 4537/4885 |
| US-20160251334-A1 | MANUFACTURING PROCESS FOR PYRIMIDINE DERIVATIVES | UMPS, HPRT1, NUDT1 | SLC6A1 430/4885GABRA5 608/4885GABRB2 2915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.